These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30981853)

  • 1. Clinical presentation and prognosis of immunoglobulin light-chain amyloidosis with high percentage of bone marrow plasma cells.
    Zhang CL; Qiu Y; Shen KN; Miao HL; Feng J; Cao XX; Zhang L; Jiang XY; Zhou DB; Li J
    Leuk Res; 2019 Jun; 81():19-24. PubMed ID: 30981853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis.
    Muchtar E; Gertz MA; Kourelis TV; Sidana S; Go RS; Lacy MQ; Buadi FK; Dingli D; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Lisa Hwa Y; Gonsalves W; Warsame R; Russell S; Lust JA; Lin Y; Zeldenrust S; Rajkumar SV; Kyle RA; Kumar SK; Dispenzieri A
    Leukemia; 2020 Apr; 34(4):1135-1143. PubMed ID: 31758090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome.
    Tovar N; Rodríguez-Lobato LG; Cibeira MT; Magnano L; Isola I; Rosiñol L; Bladé J; Fernández de Larrea C
    Amyloid; 2018 Jun; 25(2):79-85. PubMed ID: 29482381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation.
    Dittus C; Uwumugambi N; Sun F; Sloan JM; Sanchorawala V
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1729-1732. PubMed ID: 27296954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis.
    Kourelis TV; Kumar SK; Gertz MA; Lacy MQ; Buadi FK; Hayman SR; Zeldenrust S; Leung N; Kyle RA; Russell S; Dingli D; Lust JA; Lin Y; Kapoor P; Rajkumar SV; McCurdy A; Dispenzieri A
    J Clin Oncol; 2013 Dec; 31(34):4319-24. PubMed ID: 24145344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p.
    Wong SW; Hegenbart U; Palladini G; Shah GL; Landau HJ; Warner M; Toskic D; Jaccard A; Hansen T; Bladé J; Cibeira MT; Kastritis E; Dispenzieri A; Wechalekar A; Varga C; Schönland SO; Comenzo RL
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e493-e499. PubMed ID: 30104177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis.
    Sidana S; Tandon N; Gertz MA; Dispenzieri A; Ramirez-Alvarado M; Murray DL; Kourelis TV; Buadi FK; Kapoor P; Gonsalves W; Warsame R; Lacy MQ; Kyle RA; Rajkumar SV; Kumar SK; Leung N
    Br J Haematol; 2019 May; 185(4):701-707. PubMed ID: 30836444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features.
    Sidana S; Larson DP; Greipp PT; He R; McPhail ED; Dispenzieri A; Murray DL; Dasari S; Ansell SM; Muchtar E; Gonsalves WI; Kourelis TV; Ramirez-Alvarado M; Kapoor P; Rajkumar SV; Lacy MQ; Buadi FK; Leung N; Kyle RA; Kumar SK; King RL; Gertz MA
    Leukemia; 2020 May; 34(5):1373-1382. PubMed ID: 31780812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation.
    Sidiqi MH; Aljama MA; Jevremovic D; Morice WG; Timm M; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Gonsalves WI; Kumar S; Kapoor P; Kourelis T; Leung N; Hogan WJ; Gertz M
    Haematologica; 2018 Jul; 103(7):1229-1234. PubMed ID: 29674497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis.
    Oke O; Sethi T; Goodman S; Phillips S; Decker I; Rubinstein S; Concepcion B; Horst S; Jagasia M; Kassim A; Harrell SL; Langone A; Lenihan D; Rawling KT; Slosky D; Cornell RF
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1473-1477. PubMed ID: 28546074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study.
    Jain T; Kosiorek HE; Kung ST; Shah VS; Dueck AC; Gonzalez-Calle V; Luft S; Reeder CB; Adams R; Noel P; Larsen JT; Mikhael J; Bergsagel L; Stewart AK; Fonseca R
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):486-492.e1. PubMed ID: 29753692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first-line treatment of systemic light chain amyloidosis in the UK.
    Sharpley FA; Manwani R; Petrie A; Mahmood S; Sachchithanantham S; Lachmann HJ; Martinez De Azcona Naharro A; Gillmore JD; Whelan CJ; Fontana M; Cohen O; Hawkins PN; Wechalekar AD
    Eur J Haematol; 2021 Apr; 106(4):537-545. PubMed ID: 33460466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up.
    Basset M; Kimmich CR; Schreck N; Krzykalla J; Dittrich T; Veelken K; Goldschmidt H; Seckinger A; Hose D; Jauch A; Müller-Tidow C; Benner A; Hegenbart U; Schönland SO
    Br J Haematol; 2021 Oct; 195(2):230-243. PubMed ID: 34341985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of Cardiac Light-Chain Amyloidosis in the Era of Novel Therapy　- A Single-Center Cohort Study of 227 Patients.
    Feng J; Zhang C; Shen K; Sun J; Fang Q; Zhang L; Cao X; Zhou D; Li J; Tian Z
    Circ J; 2019 Mar; 83(4):775-782. PubMed ID: 30773521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis.
    Sidiqi MH; Aljama MA; Jevremovic D; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Gonsalves WI; Kumar S; Kapoor P; Kourelis T; Leung N; Hogan WJ; Gertz MA
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2360-2364. PubMed ID: 29964192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of bone marrow plasma cells percentage on survival at diagnosis and pre-transplant period in newly diagnosed multiple myeloma: Experience of a single center from Turkey.
    Ciftciler R; Goker H; Buyukasık Y; Aladag E; Saglam EA; Demiroglu H
    Transfus Apher Sci; 2019 Jun; 58(3):313-317. PubMed ID: 30928228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical presentation and prognostic analysis of Chinese patients with systemic light chain amyloidosis with liver involvement.
    Zhang LL; Shen KN; Zhang CL; Qiu Y; Miao HL; Feng J; Cao XX; Zhang L; Zhou DB; Li J
    Leuk Res; 2019 Nov; 86():106226. PubMed ID: 31541941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.
    Shen KN; Feng J; Huang XF; Zhang CL; Zhang CL; Cao XX; Zhang L; Zhou DB; Li J
    Ann Hematol; 2017 Dec; 96(12):2089-2094. PubMed ID: 28956112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
    Schwotzer R; Manz MG; Pederiva S; Waibel C; Caspar C; Lerch E; Flammer AJ; Brouwers S; Seeger H; Heimgartner R; Fehr T; Rossi D; Bianchi E; Stüssi G; Ghilardi G; Gerber B
    Hematol Oncol; 2019 Dec; 37(5):595-600. PubMed ID: 31486522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.